Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alpha Cognition Inc.

< Previous 1 2 Next >
Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Present Clinical Data at ASCP Annual Meeting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces Partial Exercise of Over-allotment Option
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Voluntary Delisting from CSE
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Appointment of VP Finance and Accounting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Change of Officer
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.